Cronos Group (NASDAQ: CRON) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its competitors? We will compare Cronos Group to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.
Institutional & Insider Ownership
12.1% of Cronos Group shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 7.9% of Cronos Group shares are held by company insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cronos Group has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Cronos Group’s competitors have a beta of 2.56, meaning that their average stock price is 156% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Cronos Group and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cronos Group Competitors||136||361||413||14||2.33|
Cronos Group presently has a consensus target price of $9.83, indicating a potential upside of 81.09%. As a group, “Medicinals & botanicals” companies have a potential upside of 111.32%. Given Cronos Group’s competitors higher probable upside, analysts clearly believe Cronos Group has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Cronos Group and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cronos Group||$25.64 million||$1.17 billion||8.10|
|Cronos Group Competitors||$218.50 million||-$99.79 million||1.73|
Cronos Group’s competitors have higher revenue, but lower earnings than Cronos Group. Cronos Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Cronos Group and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cronos Group Competitors||-163.69%||-267.59%||-46.37%|
Cronos Group competitors beat Cronos Group on 7 of the 13 factors compared.
About Cronos Group
Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, retail, and hospitality partner channels. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Its brand portfolio includes PEACE NATURALS, a global wellness platform; adult-use brands comprise COVE and Spinach; and hemp-derived CBD brands consists of Lord Jones and PEACE+. Cronos Group Inc. is based in Toronto, Canada.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.